(Q43030471)

12 November 2017

title

Role of cell surface molecules and autologous ascitic fluid in determining efficiency of adenoviral transduction of ovarian cancer cells (English)

1 reference

12 November 2017

1 reference

1 reference

N Ingram

1

1 reference

12 November 2017

L P MacCormac

2

1 reference

12 November 2017

N T Oxley

3

1 reference

12 November 2017

P A Burns

4

1 reference

12 November 2017

G D Hall

5

1 reference

12 November 2017

publication date

11 June 2010

1 reference

12 November 2017

1 reference

12 November 2017

volume

17

1 reference

12 November 2017

issue

10

1 reference

12 November 2017

page(s)

684-693

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2010.24

12 November 2017

exact match

0 references

cites work

Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Adenoviral-mediated suicide gene therapy for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphavbeta3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Primary culture and mRNA analysis of human ovarian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Transcriptional targeting of acute hypoxia in the tumour stroma is a novel and viable strategy for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Ovarian surface epithelium: biology, endocrinology, and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Titer determination of Ad5 in blood: a cautionary note

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Inhibition of ovarian tumor growth by gene therapy with recombinant soluble vascular endothelial growth factor receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Adenovirus serotype 5 hexon mediates liver gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

Adenovirus-mediated thymidine kinase gene therapy for recurrent ovarian cancer: expression of coxsackie-adenovirus receptor and integrins alphavbeta3 and alphavbeta5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

inferred from DOI database lookup

7 January 2021

based on heuristic

Expression of CD40 in ovarian cancer and adenovirus-mediated CD40 ligand therapy on ovarian cancer in vitro

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.24

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CGT.2010.24

1 reference

Dimensions Publication ID

12 November 2017

1030692687

0 references

1 reference